Gene therapy shot around the eye aims to reduce bulging in thyroid eye disease

NCT ID NCT07404111

Not yet recruiting Disease control Sponsor: Kriya Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new gene therapy called VV-14305, given as an injection around the eye, for people with moderate to severe thyroid eye disease. The trial will include 110 adults and is split into two parts: first to check safety, then to compare the treatment against a sham injection. The main goal is to see if the treatment can safely reduce eye bulging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VV-14305 (a gene therapy given as an injection around the eye)
What this could lead to: If it works, this could provide a new treatment option to reduce eye bulging and other symptoms of thyroid eye disease.
What could go wrong: This is an early phase 1/2 trial with only 110 participants, so safety and effectiveness are not yet proven. Gene therapies can have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE, TED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID EYE DISEASE, TED

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Kriya Clinical Trial Site

Auckland, New Zealand, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.